Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tuspetinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 175,273Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose Spotlights Tuspetinib's AML Responses at ASH 2025
    Aptose Spotlights Tuspetinib's AML Responses at ASH 2025

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/06/3201046/35575/en/Aptose-s-Tuspetinib-Triple-Drug-Therapy-Featured-at-the-2025-ASH-Annual-Meeting-High-Rate-of-Frontline-Clinical-Responses-Continues-Across-AML-Populations.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Aptose Reports Third Quarter 2025 Results
    Aptose Reports Third Quarter 2025 Results

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187912/35575/en/Aptose-Reports-Third-Quarter-2025-Results.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH
    Aptose Tuspetinib Data In Newly Diagnosed AML Chosen For ASH

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179367/35575/en/Aptose-Tuspetinib-Clinical-Data-from-Ongoing-TUSCANY-Trial-in-Newly-Diagnosed-AML-Selected-for-Presentation-at-the-2025-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Aptose’s Tuspetinib Excels with Standard Care in AML Patients
    Aptose’s Tuspetinib Excels with Standard Care in AML Patients

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167802/35575/en/Aptose-s-Tuspetinib-Exceeds-Expectations-When-Combined-with-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Aptose, Hanmi Pharma Extend Loan For Tuspetinib In Aml Triplet
    Aptose, Hanmi Pharma Extend Loan For Tuspetinib In Aml Triplet

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153823/35575/en/Aptose-and-Hanmi-Pharmaceutical-Extend-Loan-Agreement-to-Continue-Development-of-Tuspetinib-in-Triplet-Therapy-for-AML.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Aptose's Tuspetinib boosts AML treatment in Phase 1/2 Trial
    Aptose's Tuspetinib boosts AML treatment in Phase 1/2 Trial

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/18/3134929/35575/en/Aptose-Reports-Early-Data-Demonstrating-Tuspetinib-Improves-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML-in-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.